Varian And Antigen Effects Propel Siemens Healthineers To New Heights In FY21

 
• By Ashley Yeo

Siemens Healthineers became only the fifth medtech to exceed $20bn annual revenues when it reported FY21 results, a performance that included exceptional elements and positive core IVD business developments.

Treatment for malignant cancer cells in a human body caused by environmental carcinogens and genetics as a target aiming at the cancerous cell as an immunotherapy therapy as a 3D illustration.

More from Business

More from Medtech Insight